RAPT TherapeuticsRAPT
RAPT
About: RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Employees: 67
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 6 (+1) [Q1 2025]
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
1% more funds holding
Funds holding: 91 [Q4 2024] → 92 (+1) [Q1 2025]
4% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 26
20% less capital invested
Capital invested by funds: $199M [Q4 2024] → $160M (-$39.5M) [Q1 2025]
263.62% less ownership
Funds ownership: 362.96% [Q4 2024] → 99.34% (-263.62%) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
29%
downside
Avg. target
$20
77%
upside
High target
$31
174%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
JP Morgan Anupam Rama | 24%upside $14 | Neutral Upgraded | 30 Jul 2025 |
LifeSci Capital | 174%upside $31 | Outperform Initiated | 22 Jul 2025 |
HC Wainwright & Co. Emily Bodnar | 139%upside $27 | Buy Maintained | 10 Jul 2025 |
UBS Eliana Merle | 29%downside $8 | Neutral Maintained | 22 May 2025 |
Financial journalist opinion
Based on 4 articles about RAPT published over the past 30 days
Positive
Zacks Investment Research
2 weeks ago
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
2 weeks ago
Best Momentum Stocks to Buy for July 15th
FUTU, IVZ and RAPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2025.
Positive
Zacks Investment Research
2 weeks ago
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?
The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
2 weeks ago
New Strong Buy Stocks for July 15th
FUTU, PAAS, RAPT, HG and IVZ have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2025.
Neutral
GlobeNewsWire
1 month ago
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E (“IgE”), a key driver of several allergic diseases. RPT904 is currently completing Phase 2 trials in chronic spontaneous urticaria and asthma, and RAPT plans to initiate a Phase 2 clinical trial for food allergy later this year.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know
The consensus price target hints at a 282.7% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 month ago
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025.
Neutral
GlobeNewsWire
1 month ago
RAPT Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June:
Positive
Zacks Investment Research
2 months ago
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
2 months ago
RAPT Therapeutics Reports First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the first quarter ended March 31, 2025.
Charts implemented using Lightweight Charts™